CBP 307

Drug Profile

CBP 307

Alternative Names: CBP-307

Latest Information Update: 28 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Suzhou Connect Biopharmaceuticals
  • Class Anti-inflammatories; Antipsoriatics; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Crohn's disease; Ulcerative colitis
  • No development reported Autoimmune disorders

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in Australia (PO, Capsule)
  • 24 Apr 2018 Suzhou Connect Biopharmaceuticals plans a phase II trial for Ulcerative colitis and Crohn's disease in China in the first half of 2018 (Suzhou Connect Biopharmaceuticals Pipeline, April 2018)
  • 20 Nov 2014 CBP 307 is available for licensing in (excluding China) as of 06 Nov 2014. http://www.connectbiopharm.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top